Suppr超能文献

无血浆铜蓝蛋白血症:一种罕见但重要的铁过载病因。

Aceruloplasminaemia: a rare but important cause of iron overload.

作者信息

Doyle Adam, Rusli Ferry, Bhathal Prithi

机构信息

Department of Gastroenterology and Hepatology, Monash Health, Melbourne, Victoria, Australia.

Department of Pathology, University of Melbourne, Melbourne, Victoria, Australia.

出版信息

BMJ Case Rep. 2015 May 14;2015:bcr2014207541. doi: 10.1136/bcr-2014-207541.

Abstract

We present a case of a 20-year-old man referred to our service with iron overload and mildly deranged liver biochemistry. Although liver histopathology was consistent with haemochromatosis, iron studies were not consistent with this diagnosis. Serum ceruloplasmin levels were undetectable, leading to a diagnosis of aceruloplasminaemia. Unlike other iron overload disorders, neurological complications are a unique feature of this illness, and often irreversible, once established. The patient was treated with iron chelation prior to the onset of neurological injury, and experienced progressive normalisation of his ferritin and liver biochemistry. This is one of the youngest diagnosed cases in the published literature and, crucially, was a rare case of diagnosis and treatment prior to the onset of neurological sequelae. This is presented alongside a review of previously published cases of aceruloplasminaemia, including responses to iron chelation therapy.

摘要

我们报告了一例20岁男性患者,因铁过载和轻度肝功能生化指标异常转诊至我院。尽管肝脏组织病理学符合血色素沉着症,但铁代谢检查结果与该诊断不符。血清铜蓝蛋白水平检测不到,从而诊断为无铜蓝蛋白血症。与其他铁过载疾病不同,神经并发症是这种疾病的独特特征,一旦出现往往不可逆转。该患者在神经损伤发生前接受了铁螯合治疗,其铁蛋白和肝功能生化指标逐渐恢复正常。这是已发表文献中诊断出的最年轻病例之一,关键的是,这是神经后遗症出现之前罕见的诊断和治疗案例。本文还对之前发表的无铜蓝蛋白血症病例进行了综述,包括对铁螯合治疗的反应。

相似文献

1
Aceruloplasminaemia: a rare but important cause of iron overload.
BMJ Case Rep. 2015 May 14;2015:bcr2014207541. doi: 10.1136/bcr-2014-207541.
2
Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation.
J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):467-70. doi: 10.1136/jnnp.2007.120568. Epub 2007 Oct 2.
3
Aceruloplasminaemia: a disorder of diabetes and neurodegeneration.
Intern Med J. 2017 Jan;47(1):115-118. doi: 10.1111/imj.13309.
4
Aceruloplasminaemia: a family with a novel mutation and long-term therapy with deferasirox.
Horm Metab Res. 2015 Apr;47(4):303-8. doi: 10.1055/s-0034-1383650. Epub 2014 Aug 4.
5
Iron chelation therapy to prevent the manifestations of aceruloplasminemia.
Neurology. 2015 Sep 22;85(12):1085-6. doi: 10.1212/WNL.0000000000001956. Epub 2015 Aug 26.
8
Iron chelation therapy in myelodysplastic syndrome - Cui bono?
Leukemia. 2009 Aug;23(8):1373. doi: 10.1038/leu.2009.39.
9
Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
Br J Haematol. 2010 Dec;151(5):504-8. doi: 10.1111/j.1365-2141.2010.08346.x. Epub 2010 Oct 18.
10
Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Expert Rev Hematol. 2016;9(2):151-68. doi: 10.1586/17474086.2016.1126176. Epub 2015 Dec 19.

引用本文的文献

1
Moonlighting enzymes: when cellular context defines specificity.
Cell Mol Life Sci. 2023 Apr 24;80(5):130. doi: 10.1007/s00018-023-04781-0.
2
Hepatic SEL1L-HRD1 ER-associated degradation regulates systemic iron homeostasis via ceruloplasmin.
Proc Natl Acad Sci U S A. 2023 Jan 10;120(2):e2212644120. doi: 10.1073/pnas.2212644120. Epub 2023 Jan 3.
4
Dementia as a core clinical feature of a patient with aceruloplasminemia.
Clin Case Rep. 2022 Mar 13;10(3):e05581. doi: 10.1002/ccr3.5581. eCollection 2022 Mar.
6
Emerging Disease-Modifying Therapies in Neurodegeneration With Brain Iron Accumulation (NBIA) Disorders.
Front Neurol. 2021 Apr 15;12:629414. doi: 10.3389/fneur.2021.629414. eCollection 2021.
10
Aceruloplasminemia: A Severe Neurodegenerative Disorder Deserving an Early Diagnosis.
Front Neurosci. 2019 Apr 5;13:325. doi: 10.3389/fnins.2019.00325. eCollection 2019.

本文引用的文献

1
Case of presymptomatic aceruloplasminemia treated with deferasirox.
Hepatol Res. 2014 Nov;44(12):1253-8. doi: 10.1111/hepr.12292. Epub 2014 Jan 23.
2
Aceruloplasminemia: a rare disease - diagnosis and treatment of two cases.
Rev Bras Hematol Hemoter. 2011;33(5):389-92. doi: 10.5581/1516-8484.20110104.
3
Desferrioxamine treatment of aceruloplasminemia: Long-term follow-up.
Mov Disord. 2011 Sep;26(11):2142-4. doi: 10.1002/mds.23797. Epub 2011 May 18.
4
Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation.
J Hepatol. 2010 Dec;53(6):1101-7. doi: 10.1016/j.jhep.2010.04.039. Epub 2010 Aug 4.
5
The neurological presentation of ceruloplasmin gene mutations.
Eur Neurol. 2008;60(4):200-5. doi: 10.1159/000148691. Epub 2008 Jul 30.
6
Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation.
J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):467-70. doi: 10.1136/jnnp.2007.120568. Epub 2007 Oct 2.
7
Copper and iron disorders of the brain.
Annu Rev Neurosci. 2007;30:317-37. doi: 10.1146/annurev.neuro.30.051606.094232.
8
Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate.
Brain Dev. 2007 Aug;29(7):450-3. doi: 10.1016/j.braindev.2007.01.001. Epub 2007 Feb 20.
9
Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights.
J Hepatol. 2002 Jun;36(6):851-6. doi: 10.1016/s0168-8278(02)00042-9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验